CN107937538B - Glioma diagnosis marker circ1:201817088|201817285 and application - Google Patents
Glioma diagnosis marker circ1:201817088|201817285 and application Download PDFInfo
- Publication number
- CN107937538B CN107937538B CN201711454282.2A CN201711454282A CN107937538B CN 107937538 B CN107937538 B CN 107937538B CN 201711454282 A CN201711454282 A CN 201711454282A CN 107937538 B CN107937538 B CN 107937538B
- Authority
- CN
- China
- Prior art keywords
- glioma
- circ1
- serum
- exosome
- detecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000032612 Glial tumor Diseases 0.000 title claims abstract description 34
- 206010018338 Glioma Diseases 0.000 title claims abstract description 34
- 238000003745 diagnosis Methods 0.000 title abstract description 15
- 239000003550 marker Substances 0.000 title abstract description 9
- 210000001808 exosome Anatomy 0.000 claims abstract description 35
- 210000002966 serum Anatomy 0.000 claims abstract description 28
- 230000014509 gene expression Effects 0.000 claims abstract description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 15
- 238000010839 reverse transcription Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000003753 real-time PCR Methods 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 abstract description 4
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000011160 research Methods 0.000 description 6
- 108091028075 Circular RNA Proteins 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 201000007983 brain glioma Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960001701 chloroform Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000013211 curve analysis Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000011528 liquid biopsy Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of biology, and discloses a glioma diagnosis marker circ1:201817088|201817285 and application thereof. In the present invention, the expression level of circ1:201817088|201817285 in the serum exosome of glioma patients was found to be significantly higher (P ═ 0.003) compared with the control group for the first time, and ROC analysis showed that it has higher diagnostic value for glioma (AUC ═ 0.937, P ═ 0.004, sensitivity and specificity of 85.7% and 88.9%, respectively). Therefore, by detecting the expression level of circ1:201817088|201817285 in the serum exosome of the glioma patient, the early and rapid noninvasive diagnosis of the glioma patient can be made.
Description
Technical Field
The invention belongs to the technical field of biology, and relates to a serum circRNA marker circ1:201817088|201817285 for glioma diagnosis, application of a reagent for detecting the marker in preparation of a glioma diagnosis preparation, and a kit.
Background
Brain glioma is the most frequent brain tumor disease of adults, and accounts for 40.49 percent of intracranial tumors. From the time of diagnosis, the average life span of brain glioma patients does not exceed five years. In order to diagnose glioma, a malignant disease with a very high genetic material correlation, the pathogenesis of glioma must be explored at the molecular biological level from the aspect of genetic information expression. At present, the diagnosis and treatment methods of glioma are in the continuous improvement stage, but the survival rate of glioma patients is not obviously improved. Glioma diagnosis is still in an empirical stage based on clinical, pathological and imaging information, and once diagnosed, most of them are in middle and advanced stages, and the survival rate after surgery is not optimistic. Therefore, the research task of searching glioma diagnosis markers to screen high risk groups and correspondingly selecting reasonable subsequent treatment schemes to improve survival rate is urgent to solve in the field of neuroscience.
The circular RNA is a kind of endogenous non-coding RNA molecules which are widely and diversely present in mammalian cells and have the function of regulating gene expression, has a covalently closed circular structure, is widely present in various cells, and is also a latest research hotspot of an RNA family following microRNA (miRNA). In recent years, with the widespread use of deep sequencing technologies and the rapid development of biophysical and informatics technologies, it has been found that human transcripts of many exons can be non-linearly reverse spliced or rearranged through genes to form circular RNAs, and that they account for a significant proportion of all spliced transcripts. In recent years, it has been found that exosomes also contain a large amount of circular RNA and may play an important role. Exosomes refer to small membrane vesicles (30-150nm) containing complex RNAs and proteins, which today refer specifically to discoidal vesicles with diameters between 40-100 nm. In 1983, exosomes were first found in sheep reticulocytes, which were named "exosomes" by Johnstone in 1987. Recent studies have shown that exosomes are important molecules for cell-to-cell communication, and participate in many physiological and pathological processes. The exosome contains not only protein components but also some RNA components, such as micro RNA (miRNA), long non-coding RNA and mRNA, and circular RNA (circular RNA). The RNAs carried by the exosomes are collectively called exosome source RNAs, have complete sequence structures and biological activities, are expected to be used as liquid biopsy molecular markers, and have bright prospects in the development of precise medicine.
Disclosure of Invention
The first object of the present invention is: provides a serum exosome circRNA marker for glioma diagnosis.
The main contents comprise: a serum exosome circRNA marker circ1:201817088|201817285 for glioma diagnosis, the sequence of which is shown in SEQ NO 1. The circRNA is located on chromosome 1 of human and has a total length of 198 bp.
The second purpose of the invention is to provide the application of the reagent for detecting the expression quantity of the circRNA marker in a serum exosome in the preparation of a glioma diagnostic preparation.
It is a third object of the present invention to provide a glioma diagnostic kit capable of determining the content of circ1:201817088|201817285 in serum exosomes.
The glioma diagnostic kit contains a PCR primer for detecting the content of circ1:201817088| 201817285. Preferred primers have the sequences shown in SEQ NO 2 and 3.
The glioma diagnosis kit comprises all reagents for extracting exosome from serum, extracting RNA from the exosome and performing reverse transcription and fluorescence quantitative PCR, except a circ1:201817088|201817285 primer.
The method comprises the following steps:
(1) reagents required for extracting serum exosomes: total Exosome Isolation Reagent (fromservum), available from Invitrogen corporation under the trade designation 4478360;
(2) reagents required for the extraction of exosome RNAs: trizol reagent, trichloromethane, isopropanol, 75% ethanol and enzyme-free water;
(3) reagents required for reverse transcription, namely Random Primer (Random Primer), enzyme-free water, 5 × reverse transcription buffer solution, base triphosphate deoxynucleotide, RNase inhibitor and MMLV reverse transcriptase;
(4) reagents required for fluorescent quantitative PCR: circ1:201817088|201817285 upstream and downstream primers, GAPDH internal reference upstream and downstream primers, SYBR dye, and enzyme-free water.
The invention has the beneficial effects that:
it was first found that circ1:201817088|201817285 was significantly upregulated in serum exosomes of glioma patients compared to normal serum exosome controls (p ═ 0.003). ROC curve analysis shows that circ1:201817088|201817285 has higher diagnostic value for glioma as a biomarker (AUC ═ 0.937, sensitivity and specificity of 85.7% and 88.9%, respectively). By applying the cyclic RNA in glioma diagnosis and analysis, the glioma can be diagnosed more conveniently and accurately, a foundation is laid for a clinician to quickly and accurately master the state of an illness of a patient, the clinical treatment effect is improved, and help is provided for finding a novel micromolecular drug target with potential treatment value.
Drawings
FIG. 1 is a real-time fluorescent quantitative PCR analysis of the expression difference of circ1:201817088|201817285 in the serum of glioma patients and the exosomes of normal serum;
FIG. 2 shows the specificity and sensitivity of Roc analysis of serum exosome-derived circ1:201817088|201817285 for early diagnosis of glioma.
Detailed Description
The following is intended to further illustrate the invention in connection with the embodiments, and not to limit the invention.
First, research object
Serum samples from 40 patients with glioma were provided by Xiangya Hospital, and 15 normal serum samples were healthy individuals who were contemporaneously community disease screened. Samples for research are collected at the same period, and sampling, subpackaging and storing conditions are consistent.
Second, research method
1. Extraction of RNA from glioma/Normal serum exosomes
200. mu.l of serum was centrifuged at 2000g for 30 minutes at room temperature, the supernatant was removed by a micropipette to a new 600. mu.l centrifuge tube, 40. mu.l of an Exosome-extracting Reagent (Total Exosome Isolation Reagent (from serum), cat. No. 4478360, Invitrogen) was added thereto and shaken gently upside down, and the mixture was incubated at 4 ℃ for 45 minutes. And after incubation, centrifuging at room temperature for 10 minutes at 10000g, and removing supernatant to obtain precipitate, namely the exosome in the serum. The pellet was resuspended by adding 200. mu.l Trizol (MRC Co.), and the suspension was transferred to a new 1.5ml tube and supplemented with Trizol to 1 ml. Cleavage on ice for 15 min. After cleavage was complete, centrifugation was carried out at 12000rpm for 10min at 4 ℃ and the supernatant was transferred to a new tube. Adding 200 μ l chloroform into Tube, shaking by hand for 15-30s, standing on ice for 5min, centrifuging at 4 deg.C and 12000rpm for 15 min; carefully taking the upper water phase into a new tube, adding 0.5ml of precooled isopropanol, uniformly mixing, standing on ice for more than 20min, and centrifuging at 12000rpm for 10min at 4 ℃; discarding the supernatant, adding 1ml ethanol diluted with 75% DEPC water, mixing, centrifuging at 4 deg.C and 7500rpm for 5min, discarding the supernatant, drying at room temperature for 5-10min, and adding 10 μ l enzyme-free water to dissolve RNA. Stored at-80 ℃ and refrigerator temperatures were recorded daily by the laboratory. Preparation of cDNA
The Reaction was carried out in a total volume of 20. mu.l (total RNA 10. mu.l, Random primer 1. mu.l, enzyme-free water 1. mu.l, 5 × Reaction Buffer 4. mu.l, RI 1. mu.l, RT 1. mu.l and 10mM dNTP 2. mu.l).
Composition (I) | Dosage/tube |
Random reverse transcription primer (1. mu.M) | 1μl |
RNA samples | 10μl |
Enzyme-free water | To 12μl |
Reverse transcription first step conditions: 5 minutes at 65 DEG C
Reverse transcription second step procedure: 5 minutes at 25 ℃, 60 minutes at 42 ℃ and 5 minutes at 70 ℃.
3. Real-time fluorescent quantitative PCR
The real-time quantitative PCR is carried out by adopting specific primers (the primer sequences are shown in SEQ NO:2 and 3) synthesized by Hanhengzheng biotechnology (Shanghai) Limited company: firstly, the reverse transcription product is diluted by 10 times and mixed evenly. The 20. mu.l reaction was as follows:
composition (I) | Dosage/tube |
SYBR Premix Ex Taq | 10μl |
Primer (10. mu.M) | 0.5μl |
cDNA product (after dilution) | 5μl |
Enzyme-free water | To 20μl |
Real-time fluorescent quantitative PCR reaction program: 95 ℃ for 3 minutes, 40 cycles, 95 ℃ for 10 seconds, 60 ℃ for 30 seconds.
4. And (3) data analysis: by using 2-ΔΔCTCirc1:201817088|201817285, representing glioma serum exosomes, expressed fold relative to normal serum exosomes, where △ CT ═ CTSample(s)–CTInternal reference,ΔΔCT=ΔCTGlioma–ΔCTIs normal. The experimental data was analyzed by a relatively quantitative analysis method using GAPDH as an internal reference gene (primer sequences shown in SEQ NO: 4 and 5) and using software GraphPad Prism and SPSS 17.0.
Third, research results
1. Serum exosomes of glioma patients had significant enrichment for circ1:201817088|201817285 and were significantly upregulated (p ═ 0.003) compared to normal serum exosome controls, with specific data as shown in figure 1.
ROC curve analysis showed that circ1:201817088|201817285 as a biomarker had higher diagnostic value for glioma (AUC 0.937, sensitivity and specificity 85.7% and 88.9%, respectively), and the detailed results are shown in fig. 2.
Sequence listing
<110> Hunan ya Hospital of Zhongnan university
<120> glioma diagnosis marker circ1:201817088|201817285 and application
<160>5
<170>SIPOSequenceListing 1.0
<210>1
<211>198
<212>RNA
<213> Intelligent (Homo sapiens)
<400>1
guccauggac agaaagcugc uugggaggac ccaguggaau ggguccggga cacacuuccc 60
uggccaucag cccaacaaga ccaaucaaag cuguaccacc ugcccccacc caccgugggc 120
ccucacagca uugccucacc ucccgaggau aggacaguca aagacagcac cccaaguucu 180
cuggacucag auccucug 198
<210>2
<211>18
<212>DNA
<213> Unknown (Unknown)
<400>2
cacagcattg cctcacct 18
<210>3
<211>18
<212>DNA
<213> Unknown (Unknown)
<400>3
cctcccaagc agctttct 18
<210>4
<211>19
<212>DNA
<213> Unknown (Unknown)
<400>4
atcatcagca atgcctcct 19
<210>5
<211>18
<212>DNA
<213> Unknown (Unknown)
<400>5
catcacgcca cagtttcc 18
Claims (4)
1. The application of the reagent for detecting the expression quantity of circ1:201817088|201817285 in a serum exosome in the preparation of a glioma diagnostic preparation, wherein the sequence of the circ1:201817088|201817285 is shown as SEQ NO: 1.
2. The use of claim 1, wherein the reagent for detecting the expression level of circ1:201817088|201817285 in the serum exosome comprises PCR primers for detecting the content of circ1:201817088| 201817285.
3. The use of claim 2, wherein the primer has the sequence shown in SEQ ID Nos. 2 and 3.
4. The use of claim 2 or 3, wherein the reagent for detecting the expression level of circ1:201817088|201817285 in the exosome in serum comprises all reagents for extracting exosome from serum, extracting RNA from exosome and performing reverse transcription and fluorescence quantitative PCR, in addition to the primers of circ1:201817088| 201817285.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711454282.2A CN107937538B (en) | 2017-12-28 | 2017-12-28 | Glioma diagnosis marker circ1:201817088|201817285 and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711454282.2A CN107937538B (en) | 2017-12-28 | 2017-12-28 | Glioma diagnosis marker circ1:201817088|201817285 and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107937538A CN107937538A (en) | 2018-04-20 |
CN107937538B true CN107937538B (en) | 2020-06-30 |
Family
ID=61940619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711454282.2A Expired - Fee Related CN107937538B (en) | 2017-12-28 | 2017-12-28 | Glioma diagnosis marker circ1:201817088|201817285 and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107937538B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110205320B (en) * | 2019-06-18 | 2023-06-23 | 中国医科大学附属盛京医院 | lncRNA molecule linc00998 and application thereof in glioma treatment/prognosis evaluation |
-
2017
- 2017-12-28 CN CN201711454282.2A patent/CN107937538B/en not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
Cell-Type Specific Features of Circular RNA Expression.;Salzman et al.;《PLOS Genetics》;20130930;第9卷(第9期);e1003777 * |
Circular RNAs in the Mammalian Brain Are Highly Abundant, Conserved, and Dynamically Expressed.;Rybak-Wolf et al.;《Molecular Cell》;20151231;870-885 * |
Also Published As
Publication number | Publication date |
---|---|
CN107937538A (en) | 2018-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107385035B (en) | Serum/plasma miRNA marker related to type 2 diabetes retinopathy and application thereof | |
CN109852688B (en) | Diagnostic primer and kit for type 2 diabetes mellitus and application of non-coding RNA molecular marker | |
EP2406402A2 (en) | Method to assess human allograft status from microrna expression levels | |
CN107937532B (en) | Glioma diagnosis marker hsa _ circ _0021827 and application | |
CN112011620B (en) | Application of circ-SLC38A1 as target in medicine for inhibiting bladder cancer cells | |
CN107557472B (en) | Glioma diagnosis marker circ9:135881633|135883078 and application | |
CN107475441B (en) | Biomarker for predicting responsiveness of breast cancer patient to AT regimen neoadjuvant chemotherapy | |
CN107937538B (en) | Glioma diagnosis marker circ1:201817088|201817285 and application | |
CN107619869B (en) | Glioma diagnosis and prognosis marker circ16:85633914|85634132 and application | |
CN107937534B (en) | Glioma diagnosis marker circ1:29154696|29154910 and application | |
CN107557441B (en) | Glioma diagnosis marker Circ2:23823258|23823569 and application | |
CN107937540B (en) | Glioma diagnosis marker circ17:47618350|47619164 and application | |
CN107937529B (en) | Glioma diagnosis marker hsa _ circ _0135404 and application | |
CN114908156A (en) | CircRNA marker and application thereof | |
CN107964564B (en) | Glioma diagnosis marker circ6:34606555|34606904 and application | |
CN107937528B (en) | Glioma prognosis marker hsa _ circ _0125365 and application | |
CN107557474B (en) | Glioma diagnosis marker circ15:98707562|98708107 and application | |
CN107937531B (en) | Glioma diagnosis marker circ7:73686636|73687095 and application | |
CN107988368B (en) | Glioma diagnosis marker circ 9:33948374|33948587 and application thereof | |
CN107557471B (en) | Glioma diagnosis marker Circ6:22020339|22020542 and application | |
CN107937543B (en) | Glioma diagnosis marker circ10:72715111|72715902 and application | |
CN107937527B (en) | Glioma diagnosis marker circ1:43920404|43920928 and application | |
CN107937537B (en) | Glioma diagnosis marker circ7:42148226|42148468 and application | |
CN107653319B (en) | Glioma diagnosis marker circ8:61680968|61684188 and application | |
CN107586846A (en) | Glioma diagnosis marker Circ3:129880309|129880559 and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200630 |